Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vitality Product Clear all
Withdrawn Not applicable Interventional

Evaluate Breast Masses Using a New Method of Ultrasound Contrast to Detect Abnormal Blood Flow in Breasts

NCT00722683
View directory record Official record
Conditions
Breast Cancer, Breast Abnormalities
Interventions
Ultrasound Imaging with Contrast
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 29, 2026, 6:21 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients

NCT02211547
View directory record Official record
Conditions
Levels of Pain
Interventions
Epic 10 Diode Laser by Biolase Inc., Placebo
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 29, 2026, 6:21 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

NCT04134260
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Hormone Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
348
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 259 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Available No phase listed Expanded access

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

NCT06836648
View directory record Official record
Conditions
Prostate Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Using Light Therapy for Mild Cognitive Impairment

NCT07651787
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Amyloid Pathology
Interventions
Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

NCT03520426
View directory record Official record
Conditions
Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
Interventions
Votiva RF
Device
Lead sponsor
Walden, Jennifer L., M.D.,P.L.L.C.
Individual
Eligibility
25 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New York, New York • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 29, 2026, 6:21 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

NCT03066115
View directory record Official record
Conditions
Hypoxia, Hypercapnia
Interventions
L-NMMA, Ketorolac, Ascorbic Acid, Intravenous Catheter, Transcranial Doppler Ultrasound
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Results available

Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy

NCT03469999
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Dysport Injectable Product
Drug
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 29, 2026, 6:21 AM EDT
Not listed Phase 4 Interventional

Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

NCT04160000
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions
Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy
Device · Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Sep 29, 2026, 6:21 AM EDT
Recruiting Phase 2 Interventional

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT07553065
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
NT 201 200U and Vibe System, NT 201 300U and Vibe System, Placebo and sham
Combination Product
Lead sponsor
Vensica Therapeutics Ltd.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

NCT00408200
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation
Drug · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

NCT05206331
View directory record Official record
Conditions
Breast Cancer
Interventions
contrast enhanced mammography, Iodinated Contrast Media (ICM)
Device · Drug
Lead sponsor
Margarita Louise Zuley
Other
Eligibility
30 Years and older · Female only
Enrollment
2,089 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Active, not recruiting Not applicable Interventional

Weight, Energy, Lipids, and the Liver (WELL) Study

NCT05199948
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Soybean Oil Foods, Palm Oil Foods
Other
Lead sponsor
Ohio State University
Other
Eligibility
22 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The DEB Pilot Study

NCT03190993
View directory record Official record
Conditions
Nutritional Physiological Phenomena, Obesity
Interventions
Sugar Sweetened Solid Treatment, Sugar Sweetened Beverage Treatment
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 29, 2026, 6:21 AM EDT
Recruiting Phase 2 Interventional

Window of Opportunity in Preserving Laryngeal Function Trial

NCT07423078
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Interventions
Toripalimab, Carboplatin, Cisplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Matthew Spector
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Not yet recruiting Not applicable Interventional

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

NCT07274787
View directory record Official record
Conditions
GBM
Interventions
NaviFUS System, Lumason, Bevacizumab
Device · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830
View directory record Official record
Conditions
Lung Adenocarcinoma, Lung Large Cell Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Durvalumab, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Methoxyamine, Pemetrexed, Radiation Therapy
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
34
States / cities
Buena Park, California • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Recruiting Not applicable Interventional

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
View directory record Official record
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Not yet recruiting Phase 3 Interventional

Vibegron for ENergy Thinking and Resilience in Aging

NCT06987383
View directory record Official record
Conditions
Obesity
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
45 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Coffee Fruit Concentrate Pilot Study 1

NCT01965795
View directory record Official record
Conditions
Brain-derived Neurotrophic Factor (BDNF), Cognitive Function, Affect
Interventions
Whole Coffee Fruit Concentrate (WCFC), Nutrim
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2015 · Synced Sep 29, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Soy Protein and Breast Cancer Risk Reduction

NCT00204477
View directory record Official record
Conditions
Breast Cancer
Interventions
soy milk, cow's milk
Dietary Supplement
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 29, 2026, 6:21 AM EDT